CCL5 and myocardial infarction: CCL5 has been shown to be highly expressed in the peripheral circulation after MI, and blocking CCL5 lowers serum levels of neutrophil and monocyte chemo-attractants during chronic myocardial ischemia while anti-CCL5 monoclonal antibody therapy improves post-MI “clinical” outcomes, such as survival and cardiac function (41).